Share Price | Kalaris Therapeutics, Inc. Stock Analysis & Recommendation

Q: Is Kalaris Therapeutics, Inc. technically bullish or bearish?

As of 1 October 2023, the technical stance for Kalaris Therapeutics, Inc. is mildly bullish overall, driven by a mix of indicators. The MACD shows a mildly bullish trend on both weekly and monthly time frames, while the Dow Theory also indicates a mildly bullish stance across the same periods. However, the weekly RSI is bearish, contrasting with a bullish monthly RSI. The Bollinger Bands are bullish weekly but mildly bearish monthly, and the daily moving averages are mildly bearish. The KST is mildly bullish weekly but bearish monthly. In terms of performance, Kalaris has significantly underperformed the S&P 500 over longer time frames, with a 1-year return of -74.89% compared to the S&P's 17.14%, but it has outperformed the index over the past week and month, with returns of 2.57% and 75.60%, respectively.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

52.48 k

Shareholding (Dec 2025)

FII

2.35%

Held by 29 FIIs

DII

18.92%

Held by 5 DIIs

Promoter

75.54%

Is Kalaris Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of October 1, 2023, Kalaris Therapeutics, Inc. shows a mildly bullish technical stance overall, with mixed indicators; despite a significant 1-year underperformance of -74.89% compared to the S&P 500's 17.14%, it has outperformed the index recently with returns of 2.57% over the past week and 75.60% over the past month.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 165 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.83

Return on Equity

-999,999.00%

Price to Book

3.94

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-32.34%

6 Months

37.58%

1 Year

-1.64%

2 Years

-61.01%

3 Years

69.85%

4 Years

-94.94%

5 Years

-98.7%

Kalaris Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

0.19%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

79.08%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.94

EV to EBIT

-1.61

EV to EBITDA

-1.61

EV to Capital Employed

-2.54

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-126.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 17 Schemes (3.19%)

Foreign Institutions

Held by 29 Foreign Institutions (2.35%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 15.97% vs -4.39% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.80",
          "val2": "-12.70",
          "chgp": "14.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.00",
          "val2": "-11.90",
          "chgp": "15.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 37.28% vs 63.66% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-46.10",
          "val2": "-51.70",
          "chgp": "10.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "2.70",
          "chgp": "-48.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.40",
          "val2": "-14.90",
          "chgp": "109.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.40",
          "val2": "-69.20",
          "chgp": "37.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]